Literature DB >> 90129

The effect of Cop 1, a synthetic polypeptide, on chronic relapsing experimental allergic encephalomyelitis in guinea pigs.

A B Keith, R Arnon, D Teitelbaum, E A Caspary, H M Wisniewski.   

Abstract

Cop 1, a synthetic polypeptide, was evaluated for its effect on a chronic relapsing form of experimental allergic encephalomyelitis (EAE). Pretreatment of juvenile Strain 13 guinea pigs with Cop 1 in incomplete Freund's adjuvant (IFA) which were subsequently challenged with guinea pig spinal cord in complete Freund's adjuvant (CFA) had a marked effect in delaying or preventing the appearance of clinical signs of EAE. Administration of Cop 1 on appearance of clinical signs of EAE prevented progression of the first episode of the disease. Although relapses were not always prevented, they were modified on their duration and intensity both clinically and histologically.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 90129     DOI: 10.1016/0022-510x(79)90058-3

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  13 in total

Review 1.  Translational research in neurology and neuroscience 2010: multiple sclerosis.

Authors:  Olaf Stüve; Bernd C Kieseier; Bernhard Hemmer; Hans-Peter Hartung; Amer Awad; Elliot M Frohman; Benjamin M Greenberg; Michael K Racke; Scott S Zamvil; J Theodore Phillips; Ralf Gold; Andrew Chan; Uwe Zettl; Ron Milo; Ellen Marder; Omar Khan; Todd N Eagar
Journal:  Arch Neurol       Date:  2010-07-12

2.  Experimental autoimmune uveoretinitis: idiotypic regulation and disease suppression.

Authors:  Y De Kozak; M Mirshahi
Journal:  Int Ophthalmol       Date:  1990-01       Impact factor: 2.031

Review 3.  Immune regulation of multiple sclerosis by CD8+ T cells.

Authors:  Sushmita Sinha; Farah R Itani; Nitin J Karandikar
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

Review 4.  New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis.

Authors:  R Arnon; M Sela; D Teitelbaum
Journal:  J Neurol       Date:  1996-04       Impact factor: 4.849

Review 5.  Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS).

Authors:  Cris S Constantinescu; Nasr Farooqi; Kate O'Brien; Bruno Gran
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

6.  Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease.

Authors:  Eric J Tarcha; Victor Chi; Ernesto J Muñoz-Elías; David Bailey; Luz M Londono; Sanjeev K Upadhyay; Kayla Norton; Amy Banks; Indra Tjong; Hai Nguyen; Xueyou Hu; Greg W Ruppert; Scott E Boley; Richard Slauter; James Sams; Brian Knapp; Dustin Kentala; Zachary Hansen; Michael W Pennington; Christine Beeton; K George Chandy; Shawn P Iadonato
Journal:  J Pharmacol Exp Ther       Date:  2012-05-25       Impact factor: 4.030

7.  Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.

Authors:  Nitin J Karandikar; Michael P Crawford; Xiao Yan; Robert B Ratts; Jason M Brenchley; David R Ambrozak; Amy E Lovett-Racke; Elliot M Frohman; Peter Stastny; Daniel C Douek; Richard A Koup; Michael K Racke
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

Review 8.  Pathophysiology of multiple sclerosis.

Authors:  Thomas Korn
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

9.  Clinical utility of glatiramer acetate in the management of relapse frequency in multiple sclerosis.

Authors:  Oscar Fernández
Journal:  J Cent Nerv Syst Dis       Date:  2012-08-29

10.  Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis.

Authors:  Christian Kleist; Elisabeth Mohr; Sadanand Gaikwad; Laura Dittmar; Stefanie Kuerten; Michael Platten; Walter Mier; Michael Schmitt; Gerhard Opelz; Peter Terness
Journal:  J Transl Med       Date:  2016-05-01       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.